Keene & Associates Inc. Decreases Stock Holdings in Pfizer Inc. (NYSE:PFE)

Keene & Associates Inc. lowered its position in Pfizer Inc. (NYSE:PFE) by 0.5% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 111,687 shares of the biopharmaceutical company’s stock after selling 534 shares during the period. Pfizer makes up about 2.5% of Keene & Associates Inc.’s portfolio, making the stock its 23rd largest position. Keene & Associates Inc.’s holdings in Pfizer were worth $3,125,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of PFE. Olistico Wealth LLC purchased a new position in Pfizer in the second quarter worth $25,000. MFA Wealth Advisors LLC acquired a new stake in shares of Pfizer in the 2nd quarter worth $29,000. Creekmur Asset Management LLC purchased a new position in Pfizer during the 4th quarter worth $32,000. Trivant Custom Portfolio Group LLC increased its position in Pfizer by 100.0% during the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 600 shares in the last quarter. Finally, Financial Connections Group Inc. purchased a new stake in Pfizer in the second quarter valued at about $34,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Up 0.4 %

Shares of PFE stock opened at $29.27 on Monday. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $34.42. The stock has a 50 day moving average of $29.21 and a 200 day moving average of $28.13. The stock has a market cap of $165.86 billion, a P/E ratio of -487.83, a P/E/G ratio of 1.04 and a beta of 0.68.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, beating the consensus estimate of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The firm had revenue of $13.28 billion during the quarter, compared to analyst estimates of $12.96 billion. During the same period in the previous year, the firm earned $0.67 EPS. The business’s quarterly revenue was up 2.1% on a year-over-year basis. As a group, sell-side analysts expect that Pfizer Inc. will post 2.66 EPS for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th were paid a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a dividend yield of 5.74%. The ex-dividend date was Friday, July 26th. Pfizer’s payout ratio is currently -2,800.00%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on PFE shares. UBS Group boosted their price target on Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 31st. StockNews.com raised shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Barclays raised their price target on shares of Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a report on Monday, September 9th. Finally, Daiwa Capital Markets raised Pfizer from a “neutral” rating to an “outperform” rating and upped their target price for the company from $28.00 to $34.00 in a research report on Wednesday, August 7th. Eight analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $34.54.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.